Therapeutic effect of dose-dense paclitaxel plus carboplatin with or without bevacizumab for Japanese patients with epithelial ovarian cancer.

Kochi, Yuki; Hosoya, Satoshi; Yanaihara, Nozomu; Nagata, Chie; Honda, Rie; Shimazaki, Miwako; Yokosu, Kota; Kuroda, Takafumi; Saito, Motoaki; Tanabe, Hiroshi; Yamada, Kyosuke; Takano, Hirokuni; Okamoto, Aikou

Background: Evidence regarding chemosensitivity to different therapeutic regimens in epithelial ovarian cancer (EOC) remains limited. This study aimed to investigate EOC implementation in daily clinical practice and reveal favorable regimens for EOC among Japanese patients. Methods: We retrospectively collected clinical data of patients newly diagnosed with EOC from 2012 to 2021 at our affiliated institutions. We evaluated overall survival (OS) and progression-free survival (PFS) of conventional paclitaxel plus carboplatin (TC) vs. dose-dense TC (ddTC) according to the eligibility of GOG262 and JGOG3016 and those with bevacizumab (BEV) vs. without BEV based on GOG218. Further, we evaluated OS and PFS of ddTC and ddTC + BEV to TC + BEV among patients with stage III/IV. Results: The ddTC group (n = 402) demonstrated longer PFS and OS than the TC group (n = 165) (adjusted hazard ratios [aHRs] [95% confidential intervals (CIs)]: 0.69 [0.55–0.88] and 0.67 [0.50–0.90], respectively). The group with BEV (n = 158) demonstrated a longer PFS than those without BEV (n = 296) (0.74 [0.57–0.95]), but not for OS (0.84 [0.60–1.17]). The ddTC and ddTC + BEV groups (n = 259 and 117) demonstrated no statistically significant differences in PFS and OS than the TC + BEV group (n = 75) (1.09 [0.79–1.50] and 0.74 [0.52–1.08] for PFS and 0.89 [0.59–1.34] and 0.73 [0.50–1.05] for OS, respectively). Conclusion: Our study may indicate ddTC, BEV, and their combination regimen as the promising first-line chemotherapy option among Japanese patients with advanced EOC.

OVARIAN epithelial cancer; JAPANESE people; OVERALL survival; PROGRESSION-free survival; SURVIVAL rate

International Journal of Clinical Oncology, 2024, Vol 29, Issue 9, p1364

1341-9625

Academic Journal

10.1007/s10147-024-02559-3